Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palazestrant With Ribociclib Versus Letrozole With Ribociclib in ER+/HER2- Advanced Breast Cancer
NCT07085767Phase 3Recruiting
- Sponsor
- Olema Oncology
- Start
- Nov 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial of palazestrant in breast cancer (2 arms), sponsored by Olema Oncology. Primary endpoint: Progression-Free Survival up to 3.5 years. Started Nov 2025; status: recruiting.
02
Drugs
palazestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07085767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07085767.